| ||||||||||||||
|
|
|||||||||||||
From the Department of Anesthesia and General Intensive Care Medicine (B), University of Vienna, Vienna, Austria
Address correspondence and request for reprints to: Burkhard Gustorff, MD, DEAA, Department of Anesthesia and General Intensive Care Medicine (B), University of Vienna, Währinger-Gürtel 1820, A-1090 Vienna, Austria. Address email to burkhard.gustorff{at}univie.ac.at
We tested the responsiveness of measures of hyperalgesia in a model of UVB-induced inflammatory hyperalgesia with remifentanil, gabapentin, and the combination of both drugs in a double-blinded, active placebo-controlled, 4-way-crossover design in 16 volunteers. A circular skin area was irradiated with UVB-light 20 h before the application of gabapentin (600 mg) and 2 h later remifentanil (0.08 µg · kg-1 · min-1, 40 min). In the sunburn spots we observed stable decreases of the heat pain perception thresholds (HPPT, mean difference, 4.45°C; 95% confidence interval [CI], 3.32°5.59°) and heat pain tolerance thresholds (HPTT; mean difference, 5.43°C; 95% CI, 4.50°6.35°) compared with normal skin. Further, large areas of mechanical hyperalgesia to pinprick adjacent to the erythema spots developed in all subjects. Overall remifentanil increased the HPPT (mean increase, 2.47°C; 95% CI, 1.86°3.09°, P < 0.001) and HPTT (mean increase, 3.18°C; 95% CI, 2.65°3.71°, P < 0.001) and reduced the area of secondary hyperalgesia by 59% (mean decrease, 5326 mm2; 95% CI, 42336419 mm2, P < 0.001) compared with placebo. In the sunburn remifentanil markedly increased the HPTT by 86% compared with normal skin (additional increase, 2.57°C; 95% CI, 1.71°3.43°). This different effect was not seen in the HPPT. With the exception of a small increase of HPTT in the sunburn (P = 0.02) gabapentin had no noticeable effect on either hyperalgesia. In conclusion, opioid analgesia was reliably demonstrated in this new extended pain model.
IMPLICATIONS: Opioid analgesia was reliably demonstrated in a new inflammatory model of primary and secondary hyperalgesia. Gabapentin showed no antihyperalgesic and no opioid-enhancing effect in this model.
This article has been cited by other articles:
![]() |
D. J. Rowbotham Editorial II: Gabapentin: a new drug for postoperative pain? Br. J. Anaesth., February 1, 2006; 96(2): 152 - 155. [Full Text] [PDF] |
||||
![]() |
T. Sycha, D. Samal, B. Chizh, S. Lehr, B. Gustorff, P. Schnider, and E. Auff A Lack of Antinociceptive or Antiinflammatory Effect of Botulinum Toxin A in an Inflammatory Human Pain Model Anesth. Analg., February 1, 2006; 102(2): 509 - 516. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. D. Iannetti, L. Zambreanu, R. G. Wise, T. J. Buchanan, J. P. Huggins, T. S. Smart, W. Vennart, and I. Tracey From The Cover: Pharmacological modulation of pain-related brain activity during normal and central sensitization states in humans PNAS, December 13, 2005; 102(50): 18195 - 18200. [Abstract] [Full Text] [PDF] |
||||
|